Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nepafenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.62 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nepafenac SCHEMBL29377340 | 1.00 | ABCB11 (0.62) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL30777846 | 0.89 | ABCB11 (0.78) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL24249 | 0.89 | ABCB11 (0.78) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| SCHEMBL20901393 | 0.88 | ABCB11 (0.59) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL42390 | 0.87 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9998546 | 0.87 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL11168965 | 0.87 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9747734 | 0.87 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL9747027 | 0.87 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Amfenac SCHEMBL11726346 | 0.87 | ABCB11 (0.76) | ABCB11LMNAPTGS1ADORA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6775 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4695324-A1 | BIO-ORTHOGONAL HYDROGELS FOR SUSTAINED RELEASE DRUG DELIVERY | Ocular Therapeutix, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4683964-A2 | POLY(ETHYLENE GLYCOL) BASED DENDRIMER-LIKE HYPERBRANCHED MACROMOLECULES, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2026-01-28 | — | — | EP | claimed |
| US-12527767-B2 | Eye drops to treat chemically induced corneal damage | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2026-01-20 | — | — | US | claimed |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| EP-4665307-A1 | BIODEGRADABLE MICROPARTICLES FOR SUSTAINED DRUG DELIVERY, METHODS OF PREPARATION AND USE THEREOF | Ocular Therapeutix, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| WO-2025215027-A1 | HYDROGELS FOR USE AS VITREOUS BODY SUBSTITUTE | Universität Heidelberg (DE) | 2025-10-16 | — | — | WO | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| US-12390363-B2 | Ophthalmic drug compositions | OXULAR LIMITED (GB) | 2025-08-19 | — | — | US | claimed |
| US-12390429-B2 | Chemically and physically stable topical ophthalmic nepafenac-based formulations | MEDIVIS S.R.L. (IT) | 2025-08-19 | — | — | US | claimed |
| WO-2001028473-A1 | SUB-TENON DRUG DELIVERY | ALCON UNIVERSAL LTD. (CH) | 2001-04-26 | — | — | WO | claimed |
| WO-2001028474-A1 | OPHTHALMIC DRUG DELIVERY DEVICE | ALCON INC. (CH) | 2001-04-26 | — | — | WO | claimed |
| WO-2001015677-A2 | USE OF 5-HT1B/1D AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| CN-1129397-A | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 1996-08-21 | — | — | CN | claimed |
| EP-0716600-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1995033457-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-5475034-A | Adminstering 3-benzoylphenylacetamide derivatives | ALCON LABORATORIES, INC. (US) | 1995-12-12 | — | — | US | claimed |
| US-4313949-A | Method of producing an inhibitory effect on blood platelet aggregation | A. H. ROBINS COMPANY, INC. (US) | 1982-02-02 | — | — | US | claimed |